Key Takeaways Halozyme's Q3 adjusted EPS of $1.72 beat estimates and rose 35.4$354.3 million, driven by higher royalties from key partnered drugs.HALO raised 2025 revenue and earnings guidance on strong performance and royalty momentum.Halozyme Therapeutics (HALO) reported third-quarter 2025 adjusted earnings of $1.72 per share, which beat the Zacks Consensus Estimate of$1.63. Earnings rose 35.4% year over year.Total revenues in the third quarter increased 22% year ...